Celebrex Long-Term Safety Monitoring Results Reassure FDA

Data from long-term Celebrex (celecoxib) post-marketing studies reassure FDA of the COX-2 inhibitor's safety, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet